Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
Stopped The study was prematurely discontinued due to poor recruitment on 18th April 2013. There were no safety concerns that led to the decision to terminate.
Conditions
- Metastatic Renal Cell Carcinoma
Interventions
Sponsor
Pfizer